- Home
- TYRA vs GRDN Comparison
TYRA vs GRDN Comparison
Compare TYRA & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- GRDN
- Stock Information
- Founded
- TYRA 2018
- GRDN 2004
- Country
- TYRA United States
- GRDN United States
- Employees
- TYRA N/A
- GRDN N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- TYRA Health Care
- GRDN Consumer Staples
- Exchange
- TYRA Nasdaq
- GRDN Nasdaq
- Market Cap
- TYRA 812.7M
- GRDN 1.4B
- IPO Year
- TYRA 2021
- GRDN 2024
- Fundamental
- Price
- TYRA $14.43
- GRDN $19.86
- Analyst Decision
- TYRA Strong Buy
- GRDN Strong Buy
- Analyst Count
- TYRA 5
- GRDN 2
- Target Price
- TYRA $31.00
- GRDN $22.50
- AVG Volume (30 Days)
- TYRA 201.5K
- GRDN 269.2K
- Earning Date
- TYRA 11-07-2024
- GRDN 02-15-2025
- Dividend Yield
- TYRA N/A
- GRDN N/A
- EPS Growth
- TYRA N/A
- GRDN N/A
- EPS
- TYRA N/A
- GRDN N/A
- Revenue
- TYRA N/A
- GRDN $1,170,907,000.00
- Revenue This Year
- TYRA N/A
- GRDN $18.05
- Revenue Next Year
- TYRA N/A
- GRDN $9.55
- P/E Ratio
- TYRA N/A
- GRDN N/A
- Revenue Growth
- TYRA N/A
- GRDN 16.86
- 52 Week Low
- TYRA $11.24
- GRDN $14.16
- 52 Week High
- TYRA $29.60
- GRDN $25.74
- Technical
- Relative Strength Index (RSI)
- TYRA 42.39
- GRDN N/A
- Support Level
- TYRA $13.27
- GRDN N/A
- Resistance Level
- TYRA $14.77
- GRDN N/A
- Average True Range (ATR)
- TYRA 0.75
- GRDN 0.00
- MACD
- TYRA 0.07
- GRDN 0.00
- Stochastic Oscillator
- TYRA 50.19
- GRDN 0.00
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs, and .BHFs.